Chongqing Iron & Steel (601005.SH) intends to raise funds through private placement to Huabao Investment not exceeding 1 billion yuan.
Chongqing Iron & Steel Co., Ltd. (601005.SH) disclosed its plan to issue A-shares to specific investors, with Huabao Investment being the intended subscriber to subscribe for all the shares in cash. The total amount of funds raised in this issuance is expected not to exceed 1 billion yuan (including this amount). The funds will be used for replenishing working capital and repaying bank loans, after deducting issuance expenses, in accordance with the registration approval document issued by the China Securities Regulatory Commission for this issuance.
Chongqing Iron & Steel (601005.SH) disclosed a preliminary plan to issue A-shares to a specific entity, Huabao Investment, who intends to subscribe to all the shares with cash. The total amount of funds raised in this issuance is expected to not exceed 1 billion yuan (including this amount), and will be used for working capital and repaying bank loans after deducting issuance expenses, based on the registration approval from the China Securities Regulatory Commission.
Related Articles
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
